7 results were returned
In the recent case of InterPharma Pty Ltd v Hospira Inc (No 5)  FCA 960 the Australian Federal Court has given patentees guidance as to novelty preserving practice in the conduct of clinical trials.
On 22 May 2018, the Health Sciences Authority (the "HSA") issued a press release announcing changes to the regulatory process for medical devices ("MDs").
COVID-19 presents an unprecedented challenge to the global life sciences industry. Members of our International Life Sciences & Healthcare team, lawyers who have a wealth of hands-on experience and strong relationships ...
The Legal 500: Pharmaceutical Advertising Guide 2021 is a practical cross-border insight into pharmaceutical advertising, with contributing editor Sally Shorthose.
In response to the COVID-19 pandemic, the Australian Federal Minister for Health has exercised his power under section 41GS of the Therapeutic Goods Act 1989 (Cth) (the Act) to exempt certain medical devices from the ...
The Therapeutic Goods Administration (TGA) has been monitoring and taking action against individuals and companies capitalising on the current pandemic to market and sell products that claim to prevent or cure COVID-19.
The COVID-19 pandemic has been a catalyst for change. As businesses around the world continue to adjust to the new normal and keep abreast of the rapidly changing rules and operational capabilities, business leaders ...